Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 1

A review of ramelteon in the treatment of sleep disorders

Authors Neubauer DN

Published 8 February 2008 Volume 2008:4(1) Pages 69—79

DOI https://doi.org/10.2147/NDT.S483

David N Neubauer

Department of Psychiatry, Johns Hopkins University School of Medicine

Abstract: Ramelteon is a selective melatonin receptor (MT1 and MT2) agonist that has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep onset. It is the only approved sleep-promoting medication that does not have a direct sedating effect, but rather enhances sleep through effects on sleep regulatory mechanisms within the suprachiasmatic nucleus. Ramelteon has been shown to have no abuse liability and therefore is not scheduled by the U.S. Drug Enforcement Agency as a controlled substance. It is available as an 8 mg tablet, which should be taken approximately 30 minutes prior to bedtime. The FDA approval contains no limitation on how long the medication may be prescribed.

Keywords: circadian rhythm, insomnia, melatonin receptors, ramelteon, sleep-wake cycle

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Readers of this article also read:

Silica nanoparticles increase human adipose tissue-derived stem cell proliferation through ERK1/2 activation

Kim KJ, Joe YA, Kim MK, Lee SJ, Ryu YH, Cho DW, Rhie JW

International Journal of Nanomedicine 2015, 10:2261-2272

Published Date: 24 March 2015

Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility

Zaloga J, Janko C, Nowak J, Matuszak J, Knaup S, Eberbeck D, Tietze R, Unterweger H, Friedrich RP, Duerr S, Heimke-Brinck R, Baum E, Cicha I, Dörje F, Odenbach S, Lyer S, Lee G, Alexiou C

International Journal of Nanomedicine 2014, 9:4847-4866

Published Date: 20 October 2014

Surface modifications of silica nanoparticles are crucial for their inert versus proinflammatory and immunomodulatory properties

Marzaioli V, Aguilar-Pimentel JA, Weichenmeier I, Luxenhofer G, Wiemann M, Landsiedel R, Wohlleben W, Eiden S, Mempel M, Behrendt H, Schmidt-Weber C, Gutermuth J, Alessandrini F

International Journal of Nanomedicine 2014, 9:2815-2832

Published Date: 5 June 2014

Amorphous silica nanoparticles impair vascular homeostasis and induce systemic inflammation

Nemmar A, Albarwani S, Beegam S, Yuvaraju P, Yasin J, Attoub S, Ali BH

International Journal of Nanomedicine 2014, 9:2779-2789

Published Date: 2 June 2014

Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery

Lee CH, Lin YH, Chang SH, Tai CD, Liu SJ, Chu Y, Wang CJ, Hsu MY, Chang H, Chang GJ, Hung KC, Hsieh MJ, Lin FC, Hsieh IC, Wen MS, Huang Y

International Journal of Nanomedicine 2014, 9:311-326

Published Date: 6 January 2014

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

Deng L, Ke X, He Z, Yang D, Gong H, Zhang Y, Jing X, Yao J, Chen J

International Journal of Nanomedicine 2012, 7:5053-5065

Published Date: 19 September 2012

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia

Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A

OncoTargets and Therapy 2011, 4:149-168

Published Date: 5 September 2011

Carbon nanotube composites for glucose biosensor incorporated with reverse iontophoresis function for noninvasive glucose monitoring

Tai-Ping Sun, Hsiu-Li Shieh, Congo Tak-Shing Ching, et al

International Journal of Nanomedicine 2010, 5:343-349

Published Date: 4 May 2010

Acute visual loss and intraocular hemorrhages associated with endoscopic spinal surgery

Marilita M Moschos, Alexandros Rouvas, Alexios Papaspirou, Michael Apostolopoulos

Clinical Ophthalmology 2008, 2:937-939

Published Date: 5 December 2008

A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatments

Adam B Lewin, Eric A Storch, Gary R Geffken, Wayne K Goodman, Tanya K Murphy

Neuropsychiatric Disease and Treatment 2006, 2:21-31

Published Date: 15 March 2006